27063-92-9

Usage

Uses

Used in Pharmaceutical Research:
5-Bromo-2,4-dimethylpyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique reactivity and structural properties contribute to the development of new drugs with improved therapeutic effects.
Used in Agrochemical Production:
5-BROMO-2,4-DIMETHYLPYRIDINE is also utilized as an intermediate in the production of agrochemicals, where it plays a crucial role in the synthesis of active ingredients for crop protection and pest control.
Used in Organic Synthesis:
5-Bromo-2,4-dimethylpyridine is employed as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications across various industries.
Used in Material Science:
Due to its unique structure and reactivity, 5-Bromo-2,4-dimethylpyridine is used in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity, for applications in various fields, including catalysis, sensors, and energy storage.

InChI:InChI=1/C7H8BrN/c1-5-3-6(2)9-4-7(5)8/h3-4H,1-2H3

Upstream product

• 1193-71-1 5-amino-2,4-dimethylpyridine 
• 108-47-4 2,4-lutidine 
• 29976-20-3 3,5-dibromo-2,4-dimethylpyridine 
• 27063-93-0 3-bromo-2,4-dimethyl-pyridine 
• 23056-33-9 2-chloro-4-methyl-5-nitro-pyridine 
• 1074-99-3 2,4-dimethyl-5-nitropyridine 
• 3430-26-0 2,5-Dibromo-4-methylpyridine 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 97308-39-9 3-bromo-4,6-dimethyl-2-pyridinecarbonitrile 
• 97308-40-2 4,6-dimethyl-3-phenylethynyl-2-pyridinecarbonitrile 
• 97308-42-4 2,4-dimethyl-6-phenyl-1,7-naphthyridin-8(7H)-one 
• 97308-41-3 4,6-dimethyl-3-phenylethynyl-2-pyridinecarboxamide 
• 1001907-68-1 (4,6-dimethylpyridin-3-yl)boronic acid 

Relevant academic research and scientific papers

FACTOR XI ACTIVATION INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates

Based on structural analysis of the human 2-oxoglutarate (2OG) dependent JMJD2 histone Nε-methyl lysyl demethylase family, 3-substituted pyridine 2,4-dicarboxylic acids were identified as potential inhibitors with possible selectivity over other human 2OG oxygenases. Microwave-assisted palladium-catalysed cross coupling methodology was developed to install a diverse set of substituents on the sterically demanding C-3 position of a pyridine 2,4-dicarboxylate scaffold. The subsequently prepared di-acids were tested for in vitro inhibition of the histone demethylase JMJD2E and another human 2OG oxygenase, prolyl-hydroxylase domain isoform 2 (PHD2, EGLN1). A subset of substitution patterns yielded inhibitors with selectivity for JMJD2E over PHD2, demonstrating that structure-based inhibitor design can enable selective inhibition of histone demethylases over related human 2OG oxygenases.

HISTONE LYSINE DEMETHYLASE INHIBITORS

The invention provides a compound which is an iV-oxalylglycine derivative of formula (I): a hydroxamic acid derivative of formula (II): or a heteroaryl derivative of fomula (III): wherein n; Z1; Z2; Y1; Y2; A; p; X1; X2; m; R4; B; R5; R6; R7; R8; R9; X3; R10; R11 and R12 are as defined herein, or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the human 2-oxoglutarate-dependant JMJD2 subfamily of histone demethylases, in particular JMJD2E. Such inhibitors are useful in changing the epigenetic state of cells resulting in the inhibition / activation of chromatin remodelling, multiple gene activation / deactivation, and in treating cancer and other conditions characterised by undesirable cellular proliferation, and psychiatric disorders including depression.

Substituted pyridine-2,4-dicarboxylic acid derivatives and medicaments based on these compounds

The invention relates to substituted pyridine-2,4-dicarboxylic acid derivatives of the formula I STR1 in which R1 and R2 have the meanings given. The invention also relates to a process for the preparation of the abovementioned compo

Condensed Heteroaromatic Ring Systems. III. Synthesis of Naphthyridine Derivatives by Cyclization of Ethynylpyridinecarboxamides

Four kinds of naphthyridinones, i.e. 1,6-naphthyridin-5-one, 1,7-naphthyridin-8-one, 2,6-naphthyridin-2-one, and 2,7-naphthyridin-1-one derivatives, were commonly synthesized by the intramolecular cyclization of pyridinecarboxamides having an ethynyl group or β,β-dimethoxyethyl group adjacent to the carbamoyl group.The syntheses of the starting pyridine derivatives were easily accomplished by cross-coupling of the corresponding halopyridines with acetylenes.Keywords-intramolecular cyclization; palladium catalyst; trimethylsilylacetylene; naphthyridinone; pyridineacetaldehyde; 1(2H)-isoquinolone

SUBSTITUTED ISOCYTOSINES HAVING HISTAMINE H2-ANTAGONIST ACTIVITY

The compounds are substituted isocytosines which are histamine H 2-antagonists. Two specific compounds of the present inventon are 2-2-(5-methyl-4-imidazolylmethylthio)ethylamino!-5-(3-pyridylmethyl)-4-pyrimi done and 2-2-(3-bromo-2-pyridylmethylthio)ethylamino!-5-(4-pyridylmethyl)-4-pyrimidone .